Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment save search
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
Published: 2023-09-25 (Crawled : 21:00) - globenewswire.com
FEMY | News | $1.305 0.39% 0.38% 190K
|
Manufacturing
|
| O: 267.91%
H: 36.07%
C: 21.31%
fda solution treatment clearance market
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
Published: 2023-03-13 (Crawled : 07:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 241.08%
H: 0.62%
C: 0.08%
treatment acquire diabetes sanofi
Axcella Granted Patent for Long COVID Fatigue Treatment
Published: 2023-08-29 (Crawled : 14:00) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 221.81%
H: 39.94%
C: 23.97%
patent covid granted treatment
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
MDGL | $222.18 -2.7% -2.8% 270K
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
treatment fibrosis liver topline trial positive nash
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
BYSI | $1.81 -2.16% -2.21% 56K
|
Health Technology
|
| O: 191.8%
H: 6.76%
C: -5.41%
treatment lung cancer positive results cancer topline trial plinabulin
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Sunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer CellsA Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments
Published: 2022-04-05 (Crawled : 14:20) - biospace.com/
SBFM | $3.315 -12.76% -14.63% 2.7M
|
Professional, Scientific, and T...
|
| O: 175.22%
H: 9.32%
C: -9.81%
potential cancer market designation
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
Published: 2023-11-29 (Crawled : 12:30) - globenewswire.com
VVOS | $2.66 -2.66% 63K
|
Health Technology
|
| O: 171.75%
H: 308.97%
C: 243.67%
fda device treatment clearance therapeutics
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
Published: 2021-07-22 (Crawled : 16:00) - igcinc.us
IGC 4 | $0.4761 -18.82% -1.28% 1.3M
|
Health Technology
|
| O: 165.54%
H: 18.32%
C: -28.75%
disease alzheimer treatment patent alzheimer’s alzheimer's disease alzheimer's
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections
Published: 2020-09-30 (Crawled : 15:40) - globenewswire.com
ITRM | $1.45 -0.69% -0.69% 57K
|
Health Technology
|
| O: 155.13%
H: 48.78%
C: -35.98%
positive fda sulopenem treatment injection infections
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
SNGX | $0.42 -17.65% -21.43% 6.3M
|
Health Technology
|
| O: 150.7%
H: 17.98%
C: -35.96%
t-cell positive treatment results study
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $2.17 -6.47% -6.91% 150K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 15:00) - biospace.com/
ABVC | News | $0.9963 -2.32% -2.38% 460K
|
Wholesale Trade
|
| O: 106.45%
H: 46.09%
C: -16.41%
abv-1519 treatment fda biopharma lung cancer study submission
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2022-12-29 (Crawled : 14:00) - prnewswire.com
HOTH | $1.23 0.0% 20K
|
Health Technology
|
| O: 102.05%
H: 40.61%
C: 20.58%
ht-001 treatment fda application therapeutics therapy cancer growth
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
Published: 2023-11-13 (Crawled : 13:30) - globenewswire.com
TENX | $3.67 2.23% 2.18% 21K
|
Health Technology
|
| O: 100.38%
H: 130.23%
C: 98.34%
tnx-103 fda expected treatment clearance hypertension heart therapeutics
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
Published: 2022-12-12 (Crawled : 13:00) - biospace.com/
APVO 3 d | $0.76 6.67% 6.25% 220K
|
Health Technology
|
| O: 98.09%
H: 4.65%
C: -43.17%
apvo436 treatment leukemia trial acute myeloid leukemia aml phase 2b
U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children
Published: 2022-01-03 (Crawled : 14:30) - biospace.com/
IMMX | News | $2.25 -10.0% -11.11% 190K
|
|
| O: 98.03%
H: 23.12%
C: -18.01%
imx-110 treatment biopharma drug disease food rare pediatric disease designation cancer children designation rare
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
Published: 2023-03-09 (Crawled : 13:00) - globenewswire.com
OCEA | $1.87 4.76% 4.55% 210K
|
|
| O: 94.03%
H: 23.08%
C: 16.04%
treatment lung research potential glioblastoma
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
Published: 2022-10-19 (Crawled : 12:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 92.89%
H: 7.26%
C: -24.02%
covid-19 treatment patent granted
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.